Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.61 |
| ▸ | TEC | P42680 | 1/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.61 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.61 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753320 | 1.00 | EGFR (0.75) | EGFRERBB2FGFR1FLT1KDR | |
| SCHEMBL4087378 | 1.00 | EGFR (0.75) | EGFRERBB2FGFR1FLT1KDR | |
| SCHEMBL4089188 | 0.95 | FGFR1 (0.75) | EGFRERBB2FGFR1FLT1KDR | |
| SCHEMBL5756521 | 0.95 | FGFR1 (0.75) | EGFRERBB2FGFR1FLT1KDR | |
| SCHEMBL13604789 | 0.95 | FGFR1 (0.75) | EGFRERBB2FGFR1FLT1KDR | |
| SCHEMBL12536499 | 0.88 | EGFR (0.75) | EGFRERBB2KDREPHB4 | |
| SCHEMBL4699625 | 0.88 | EGFR (0.75) | EGFRERBB2KDREPHB4 | |
| SCHEMBL4087422 | 0.88 | EGFR (0.75) | EGFRERBB2KDREPHB4 | |
| SCHEMBL4077611 | 0.88 | EGFR (0.80) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL1382018 | 0.88 | EGFR (0.80) | EGFRERBB2RIPK2RETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| EP-1667991-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885FGFR1 211/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885FGFR1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.